This finding sheds light on the potential effect of SGLT1 and SGLT2 inhibition on protecting skeletal muscle cells, offering a novel approach to address ageing and degeneration in skeletal muscle, such as frailty and sarcopenia. Here, SLC5A1 is linked to sarcopenia.